Pulmonary Hypertension Treatments

Find Pulmonary Hypertension Treatments

Generic Name

Aspart

Brand Names

NovoLog, Remodulin, Yutrepia, Treprostinil, Orenitram, Tyvaso DPI, Tyvaso, Merilog, FiAsp

FDA approval date: August 27, 2001

Classification: Insulin Analog

Form: Injection, Inhalant, Tablet, Kit, Capsule

What is NovoLog (Aspart)?

Treprostinil injection is a prostacyclin mimetic indicated for: Treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH , PAH associated with congenital systemic-to-pulmonary shunts , or PAH associated with connective tissue diseases .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

The Impact of Inhaled Treprostinil on Dyspnea and Exercise Intolerance in Mild COPD; a Pilot and Feasibility Trial

Enrollment Status: Recruiting

Publish Date: April 09, 2026

Intervention Type: Drug, Combination product

Study Phase: Phase 2

Summary: The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT ...

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Enrollment Status: Recruiting

Publish Date: April 06, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

View All Clinical Trials